Nanocrystalline Pharmaceutical Patent Litigation: The First Case

Nanotechnology promises to have a major impact on health care. Indeed, one of the first major product success stories to come out of this emerging field is a nanoparticle-based drug for cancer therapy. Abraxane, manufactured by Abraxis, uses albumin nanoparticles to enhance the effectiveness and reduce the side effects of paclitaxel, a chemotherapy drug used for treating breast cancer. In July 2006, Elan Pharmaceuticals filed a complaint alleging that the Abraxane infringes two of Elan's patents regarding nanoparticle formulation technology. After two years of discovery battles, the dispute has finally gone before a jury, which rendered a verdict in favor of Elan for $55.2 million. In this article, IP lawyers William Prendergast and Heather Schafer provide a background of the dispute, summarize the case, and draw conclusions regarding its implications for nanotechnology patent litigation. Source

Comments

Popular posts from this blog

Databases on the FDA Website

Employee Retention – A critical issue, why..and How to solve?

IPEXL - New Patent Search Tool